Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the
8 Cheap Large Cap Stocks to Buy Now. On April 9, 2026, BofA raised the price target on Teva Pharmaceutical Industries Limited (NYSE:TEVA) to $42 from $38 and maintained a Buy rating. BofA said the update reflects changes made as part of its Q1 preview across large-cap pharma and small-to-mid cap biopharma coverage.
On March 30, 2026, Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced that its applications for a proposed biosimilar to Xolair, oromalizumab, have been accepted for review by both the U.S. FDA and the European Medicines Agency. The filings include a Biologics License Application and a Marketing Authorization Application and cover all approved indications of the reference product, including moderate-to-severe persistent allergic asthma.
Pixabay/Public Domain
On the same day, Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced FDA approval of Ponlimsi as a biosimilar to Prolia. The company said the approval covers all indications of the reference product, including treatment of postmenopausal women with osteoporosis at high risk for fracture, supported by data showing comparable efficacy, safety, and immunogenicity.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) develops and markets generic and biopharmaceutical medicines globally.
While we acknowledge the potential of TEVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.
Leave a Reply